CIPRODEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CIPRODEX (CIPRODEX).
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication; dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Ciprofloxacin is partially hepatic (CYP1A2) and renal; dexamethasone is extensively metabolized in the liver. |
| Excretion | Ciprofloxacin: 50-70% renal (glomerular filtration and tubular secretion), 20-35% biliary/fecal. Dexamethasone: renal elimination of metabolites, <5% unchanged. |
| Half-life | Ciprofloxacin: terminal elimination half-life 3-5 hours (prolonged to 5-10 hours in renal impairment). Dexamethasone: biological half-life 36-54 hours. |
| Protein binding | Ciprofloxacin: 20-40% (mainly albumin). Dexamethasone: 75-85% (mainly albumin and transcorrin). |
| Volume of Distribution | Ciprofloxacin: 2-3 L/kg (extensive tissue penetration). Dexamethasone: 0.5-1 L/kg. |
| Bioavailability | Otic: minimal systemic absorption (local effect). Ophthalmic: minimal systemic absorption. |
| Onset of Action | Otic: 30-60 minutes (bacterial inhibition). Ophthalmic: 15-30 minutes. |
| Duration of Action | Otic: 6-8 hours (requires twice-daily dosing). Ophthalmic: 4-6 hours. |
| Molecular Weight | Ciprofloxacin HCl: 385.82 g/mol; Dexamethasone: 392.46 g/mol |
| Action Class | Quinolones/ Fluroquinolones |
| Brand Substitutes | Wocipflo 500mg Tablet, Strox 500mg Tablet, Ciprodac 500 Tablet, Alciflox 500mg Tablet, Cifran OD 500mg Tablet, Cyprine FC 250mg Tablet, Cyprine 250mg Tablet, Ciprokind 250mg Tablet, Floxip 250 Tablet, Ciprodac 250 Tablet, Cipromed 750mg Tablet, Ciprolet OZ 750mg Tablet, Quilox 750mg Tablet, Floxonil 750mg Tablet, Cipromet 750mg Tablet |
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension: 4 drops into affected ear(s) twice daily for 7 days.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dosage adjustment required for ciprofloxacin/dexamethasone otic suspension due to minimal systemic absorption. |
| Liver impairment | No dosage adjustment required for ciprofloxacin/dexamethasone otic suspension due to minimal systemic absorption. |
| Pediatric use | Children (6 months and older): 4 drops into affected ear(s) twice daily for 7 days. Weight-based dosing not applicable as it is a fixed-dose otic suspension. |
| Geriatric use | No dosage adjustment required for elderly patients based on age alone. Use standard adult dosing. |
| 1st trimester | Avoid in first trimester unless benefit outweighs risk; possible risk of cartilage damage from ciprofloxacin and theoretical risk from dexamethasone. |
| 2nd trimester | Use with caution; ciprofloxacin may affect fetal cartilage development, dexamethasone potential for growth restriction with prolonged use. |
| 3rd trimester | Avoid near term; fluoroquinolones and corticosteroids may cause adverse fetal effects, including possible arthropathy and adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for CIPRODEX (CIPRODEX).
| Placental transfer | Ciprofloxacin crosses the placenta with fetal serum concentrations approximately 50-70% of maternal levels. Dexamethasone crosses the placenta but is partially metabolized; fetal exposure is significant. |
| Breastfeeding | Ciprofloxacin is excreted into breast milk in low amounts; American Academy of Pediatrics considers it compatible. Dexamethasone is also excreted but at low levels. Monitor infant for diarrhea, rash, or oral thrush. Avoid if alternative agents are available. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to ciprofloxacin, dexamethasone, or any component of the formulationViral infections of the eye including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicellaMycobacterial infections of the eyeFungal infections of the eyeUncontrolled glaucoma
| Precautions | Otic use only; not for injection or ophthalmic use, Hypersensitivity reactions including anaphylaxis, Clostridium difficile-associated diarrhea (rare with otic use), Prolonged use may lead to fungal superinfection, Not for use in patients with viral infections of the external ear including herpes simplex |
| Food/Dietary | No known food interactions for otic use. |
Loading safety data…
| Lactation Rating | L2 (Safe) |
| Teratogenic Risk | CIPRODEX (ciprofloxacin and dexamethasone) is classified as FDA Pregnancy Category C. Ciprofloxacin crosses the placenta. Fluoroquinolones are associated with arthropathy in immature animals, but human data do not show a clear increase in major malformations. However, due to potential fetal cartilage damage, use is generally avoided during pregnancy, especially in the first trimester. Dexamethasone is a corticosteroid; prolonged use may increase risk of intrauterine growth restriction and adrenal suppression. Overall, risk is considered low but not zero. |
| Fetal Monitoring | Monitor fetal growth (ultrasound) if used for prolonged periods due to corticosteroid risk. No specific monitoring for ciprofloxacin except routine antenatal care. Observe for maternal adverse effects: tendonitis, neuropathy, hypoglycemia, and ocular effects (dexamethasone). |
| Fertility Effects | No specific data on fertility impairment with CIPRODEX in humans. Ciprofloxacin has not been shown to affect fertility in animal studies. Dexamethasone may affect ovulatory cycles at high doses; no significant impact on fertility expected with topical otic use. |
| Clinical Pearls | CIPRODEX contains ciprofloxacin (0.3%) and dexamethasone (0.1%). It is indicated for acute otitis externa and acute otitis media in pediatric patients with tympanostomy tubes. Do not use in perforated tympanic membranes due to ototoxicity risk. Administer warm drops to reduce vertigo. Shake well before use. |
| Patient Advice | Use exactly as prescribed; do not skip doses. · Warm the bottle in your hands for 1-2 minutes before use to reduce dizziness. · Lie on your side with the affected ear up for 5 minutes after instillation. · Complete the full course even if symptoms improve. · Do not touch the dropper tip to any surface to avoid contamination. · Notify your doctor if you experience hearing loss, ringing, or severe dizziness. · Not for use in eyes; for otic use only. |